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Tumor cell-induced angiogenesis, i.e., new blood 
vessel formation within tumor tissue, is an essential 
requirement for the growth of solid neoplasms. In-
terleukin-12 (IL-12) inhibits growth of a variety of 
experimental tumors in vivo. We tested whether an-
titumor activity ofIL-12 is related to the inhibition of 
angiogenesis induced by tumor cell lines. Angiogen-
esis was induced in x-ray imll1unosuppressed Balb/c 
mice by intradermal injection of the following hu-
n"lan tUll10r cells: T47D, originating from Inalnll1ary 
carcinoma; A431, derived from vulval carcinoma; 
and Skv, established from bowenoid papulosis . Sys-
temic treatment of the mice with murine IL-12 sig-
nificantly decreased angiogenesis induced by human 
tumor cells in a time-and dose-dependent manner. 
Preincubation of hl1ll1an cells in vitro with IL-12 did 
not inhihit tumor cell-induced angiogenesis, sug-
I n 1.971 , Fo lkman suggested that growth of so lid tumors depends on the ability of tumor cells to induce new blood vessel formation within the tumor tissue, and that antian-giogenic compounds could be useful in the treatment of cancer (Folkman, 1971) . This hypothesis was confirmed by 
several experi mental and clinical studies showing that not only 
growth but also tumor invasiveness and metastasis are closely 
Linked to the angiogenic capacity of tumor cells (for review see: 
Bouck, 1990; Folkman, 1990, 1995; Liotta c/ ai, 1991). Experimen-
tal tumors at an early smge, as well as human carcinomas ;1/ S;/II , are 
usuaUy not angiogenic, and for several months '111d years may 
persist with no evidence of spreading (Folkman, 1990). T he 
angiogen ic phenotype of solid tumors, which enables tU1110r spread-
ing, arises during their progression , and is related to both activation 
ofsorne oncogenes and loss of the fun ction oftbe known (e.g., p53) 
and putative tumor suppressor genes (Bouck, 1990; Liotta et ai, 
1991; Folkman, 1995). Induction of tumor vasculature depends on 
the production of various angiogenic factors, e.g., vascu lar endo-
thelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF) , angiogenin, and others (Folkman, 1995) as weD as on the 
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gesting that the antiangiogenic capacity of 1L-12 is 
restricted to i11 vivo conditions. Treatment of the mice 
with rat antibody against murine interferon-I' (IFNI') 
resulted in counteracting the antiangiogenic effect of 
murine IL-12. Furthermore, human IFNI' inhibited 
the angiogenic activity of human tumor cell lines. 
This indicates that IFNI' is a mediator of the anti an-
giogenic effect of IL-12. The results show that the 
mechanism of antitumor action of IL-12 may depend 
not only on the immunostimulatory activity of this 
cytokine but also on its effect on tumor cell-induced 
angiogenesis. IL-12 should be considered as a poten-
tial candidate for the treatment of angiogenesis-
dependent ntalignancies. Key words: i."tel,le/lkilt- 12/ 
t/l"IOI' allgiogellesis/illllibitioll of (l1Igioge II es is. ] Illvest D er-
ma.to/ 106:1114-1118, 1996 
downregulatioll of severa l endogenous antiangiogenic C1ctors, c.g., 
thrombospondin, angiostatin, and other inhibitors (Rastinejad et ai, 
1989; O'Reilly c/ ai, 1994; V,U1 Meir, 1994). 
Counting il11munohistochemicall y visua lized blood vessels was 
shown to be of prognostic signifi cance in a vat;ety of human 
malignancies, including carcinomas of thc breast, cervix, head and 
neck, prostate, bladder, and colon-tumors of the central nervou 
system and melanomas (Folkman, 1995). Finally, it has been 
suggested that combination therapy with 3ntiangiogenic and cyto-
toxic ;Igents, acting both on the endothelial ceD and tumor cell 
compartments, may be more cffective than conventional chemo-
therapy (Folkman, 1990; Maione and Sharpe, 1990; Denekamp, 
1993; Gottcsm.an, 1994; Karp and Broder, 1995). One of the main 
limitations of antiangiogenic therapy is the relative high toxicity of 
antiangiogenic drugs (Maione and Sharpe, 1990; Denekamp, 
1993). Among compounds with markcd antineoplastic and antiau-
giogenic activity and controDable side effects are analogs of vitamin 
A (retinoids) , vitamin D3 (ca lcitriol), ~lI1d some cytokines (e.g .. 
interferons) (Majewski e/ ai, 1986, 1993, 1994, 1995; Sidley and 
Borden, 1987; Ingber and FoLkman, 1988) . 
Recently, a novel cytokine, interlcukin-12 (IL-12), has been 
discovc['ed and shown to exert a variety of an titumor and 3ntimeta-
static effects in experimental systems ;/1 11;110 (Brunda cl ai, 199,,: 
Brunda, 1994; Brunda and Gately, 1994; Gately e/ ai, 1994a). The 
genes for this cytokine have been cloned (Gubler c/ ai , 1991 ; WoU' 
e/ ai, 199:1) and purified recombinant protcin has been produced. 
Because antitumor and antimetastatic effects of IL-12 have been 
reported also in severe combined immunodeficient (SCID) mice 
and ill both nude and CDS-depleted mice (Brunda e/ ai, 1993), i[ 
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Figure L IL-12 dose- dependent inhibition of angiogcncsis in-
duced b y tumorigcnic T47D, A431 , and Sky cc\llincs_ Murine IL-12 
(0.3 , L.O, 3 .0 /-Lg) was injected i.p. daily for 5 days befo re induction of 
angiogenes is by injectillg 2 X 105 human tumo r cell s intradenna ll y (i.d .) 
into Jn icc . Angiogenes is is expressed as mean ± SI) nlltllbc r of newly 
fonned blood vessel s pC I' single site of i.d. illj ecti on of tumor cell s. III 
paren theses arc Illllnbcr of inj ectioll si tes. '" t stati stica ll y Sig lli fi c.lI1t inhibi-
tion of angiogenes is as compared to the control at p < 0.002. 
has been suggested that th is cyto kinc m ay afrect som e n o nimmu-
nologica l events associated with tumor prog ress ion. R ecently, 
Voes t el at (1995) ha ve shown that IL-1 2 is cap able o f inhibitin g an 
experim e ntal n eovascu larizatio n of the m ouse cornea induced b y 
bFGF- containing p e ll e ts. In t his study, we re port o n t h e stro n g 
inhibitory e ffect of IL- 1. 2 o n angiogen es is induced b y human tumo r 
cell lines in x -ray-immunosllppresse d mi ce. Furthermore . it was 
shown that IFNI' is one o f the m e diators of 1L-12 activ ity. 
MATEIUALS AND METH O DS 
Reagents Recombinant murine IL- 12 (rn IL-1 2). recombill allt humall 
1L-12 (hIL- 12), and ra t allti-mouse IFNI' neutra li zing antibody (lgG I' 
XMG 1.2) were obtained fro m Holfillanll-La R oche Inc. (Nutley, NJ). 
Human IFNI' was deri ved fro m Bioferoll G mbH (Laupheim. Germany). 
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The other reagellts were purchased from GIBCO (Paisley. UK) or Sigm a 
C hemical Co. (St. Loui s, MO). 
Cells Four types of hllman tumor cell lines were used . T4 7D cells 
o rig inated fi'om hUlll an breast carcinom a and A43 1 cells derived fi'om 
carcinom a of the vul va. Skv cell s were established ce ll lines origina ting /Tom 
boweno id papulosis of the vul va and conta ining mul tiple integrated copies 
of human papilloma virus 16 (HPV1 6) DNA (Schneide r-Ma unoUl')' CI nl. 
1990) . III pipe-passaging of these cells in lIude mice resul ted in generation of 
t\.vo sublincs differing in tUl1to rigcnic potenti a1. T he ceII s we re g rown ill IIi/HI 
in Dulbccco' s l110 difi c d Eagle ' s Ill Cdilllll supplclllcntcd "vith ·IOtX. feta l calf 
serum . N- 2-hydroxye thylpiperazinc- N ' - 2-cthanesul fon ic acid buffer. L-glu-
ta minc . and standa rd antibiotics. The ce lls wc re detached by trypsin / 
cthylcncd ial11inc tctraacc tic acid treannc il t . \vashcd in phosphate-buffe red 
sa lille, and then used for the allgiogellesis assay. In ano ther set o f expcri-
nlCllts . ce ll s were prcincuba tcd ill Iliff{) for 72 h with t11urinc o r hUtllan I L-1 2 
o r wi th human IFNI'. Fo llowing incubation , the ceUs we re washed. 
trypsi ni zed. suspended in a plane mediu llI . and illj ec ted intraderl11a ll y into 
t he m Oll se rec ipien ts. As l1 Cg:ltivc cOll t ro l. w e Ll sed 11 0 rl1wl hUI11:l11 fi bro-
blasts isolated frolll a cuta lleous biopsy from a healthy volunteer by 
overnight enzyma tic digestio n using 0. 1 % collagenase solution (Sigma). 
Angiogcnesis Assay In o rder to examine an ti angiogcnic pro pe rtie s of 
IL- 12. we used a 1l1urillC nlodcl of CUt:1I1 CO li S ang iogen esis (Kalninski ('( nl . 
1984; Majewski CI nl, 1984 . 1994). The assay is based on coun ti ng of ncwly 
formed hlood vessels in the area of intradenn,,1 injection of rumor cell s into 
imlllunosuppressed mice. III th is early phase . in cont.ra st to long-lasting 
tumorigenicity assay. tUlllo rs do not develop and onl y newly form ed 
vasc ul:l turc around injected turnor ce lls is v isibl e at th e inne r surface of the 
lllurinc skin. 
For the experiments. 4- to (.-week-old inbred Balb/ c fema le mice wcre 
used as recipiell ts of huI11 an tunl o r ce lls. T he Jni ce were inul1ul1osupp rcsscd 
by 600-R X-irradiatioll 2 h before the assay . then anestherized with 0.2 ml 
of 3.6% chlo ral hydrate. Both Aanks of the mice were shaved and injected 
intradermall y with 0. 1 ml of cell suspensions supplemented wi th a drop of 
0. 1 'X, trypall blue (fo r better visnali zation of the il~i ection site). The m ice 
received 1-2 X 10:"1 ce ll s per sing le injectio n site . and each 1l101lSC received 
up to two to fo ul' injectio n s. T h e Illic!! w c re trc~ltcd in trapcritollcnlly ,,,ieh 
IL- 12 alld / o r anti- lFNy antibody for 5 or 3 days befo re o r 3 da ys after 
;ltlg iogcncsis induc tion. Three da ys after an g iogen esis inducti o n . th e :1 l1in1 al5 
were k.i ll ed . the illne r snrfi,ce of their skin was inspected unde r the 
dissecring Illi croscopc . and the sites of cell injections were assessed accord-
ing to the ci-ircria o f Sidk), and Auerbach (1995) for the number of newly 
forllled blood vessels growi llg into the area of illjected hllmall nnn or cells. 
T hese vessels difFered m o rp hologica ll y fi'om the backgro llnd vascul" tllre b y 
thei r directioll toward the site of cell injection and by the ir tortuous 
characte r w ith man)' di va rications. All coun tings were performed blind . 
T he results were expressed as nlCi1n ± SO 1l1l11lbc r of newly forlll ed blo od 
vessels pCI' single site of ce ll illj ec tion. Statisti ca l signifi cance of differences 
was assessed b y Student's t test. 
Table I. Time Dependence of the Inhibitory Effects of Mouse IL-12 on Tumor Cell-Induced Angiogenesis " 
Tim e of IL-1 2 Administratio n 
Angiogenes is Induced Contro l 
by Cell Lincs: (no IL-(2) - 5 days -3 days + 3 da ys 
T47D 25.7 :!: 1.4 (25) 19.9 :':: 2.0 (24)" 24.0 :!: 0 .8 (6)" 18.9 :!: 1.4 ( 10)" 
N = 12 N = 12 N = 6 N = 6 
A43 1 25.6 :':: 0 .9 (29) 20.3 :!: 1.7 (23)" 23 .9 :!: 0.8 (7)" IS.c. :!: I. 1 (tI) 
N = 15 N = 12 N = 5 N = 5 
SKv- tu 25 . 1 :!: 1.4 (29) 22 .8 :!: 1.4 (27)" 24. 1 :!: 1.0 (7) 18.4 :!: 1.3 (7)" 
N = 15 N = 1-1 N = 5 N = 5 
Skv-nontu 16. 1 :!: 1.5 (8) n.d. n .d . 14.8 :!: 1.9 (8) 
N = 4 N = 4 
NHF 8.8 :!: 1. 5 ( 14) n.d . n .d . IO.I :!: 1.0( 14) 
N = 7 N = 7 
Of A ngiogencsis is cxpressed ;IS Illeiln :!: 51) llumber of newly fo rlll ed blood vessels per sing le sit·c of cell injccdo ll . Nu mhers of i.l1j l~c l"iun sires il rc given in pil rcnthcscs. ami th(' 
number af miec is il1d ic;lted ilS N . IL- 12 ( I J.Lg/ l1lo l1sc/day) was adminisle red i.p, to the recipie nt Baill i e m ice 0 11 5 o r 3 consecut ive d :lyS. hefore (- 5 o r - .1 (l:I ),s. rcspccrivdy) 
or 3 da ys afler (+ 3 d ays) the inducrio ll of Ol n g iogc l1 c liiis hy llllllo rig cnit: tumOr cell lincs: T47D. A4 3 1. Skv (Skv-w ). by lIolltu11to rigcnic Skv <:cll Iin C" (Skv-Ilon ru) o r hy no nllal 
human skill flhroblasts (NHF) . 
b Statis rica ll y li ig ni ficaur di llc rc llcc'i :H letlSI ;11 p < 0.(1) 1 as comparcd 10 rhe ('o lllrn i (anp; iogclll's ili ill mi ce Ircarco w ith vehicle) . 
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Table II. Effects of Human IL-12 on Angiogenesis Induced by Human Tumor Cells in Balb/c Mice a 
Trcatlllcnt 
Treatment of Balb/c mice with": 
Placebo 
h1L-12 
Treatment of human tumor ce ll s with' : 
T47D 
26.7 ::':: 1.2 (8) 
25.6 ::':: 2.9 (5) 
Angiogenes is Induced by Tumor Cells 
A431 
27 .3 ::':: 0.5 (8) 
27.0 ::':: 1.6 (6) 
Skv-tll 
27.3 ::':: 0.5 (8) 
27.0 ::':: 1.0 (7) 
Vehicle 
h1L-12 
18.5 ::':: 1.2 (8) 
20.1::':: 2.0 (11) 
19.2 :!: 3.5 (6) 
19.9 ::':: 1.1 (7) 
20.3 :!: 3.2 (3) 
19.5 ::':: 2.3 (11) 
" Angiogenesis is expressed as mean :t SD number of newly formed blood vessels per single site of cd l injection. Numbers of injection sires arc g iven in p;:lrcnthcscs. 
1/ Human IL-12 was injected i.p. at the dose ofl JLg/mollsc/dny for 5 days before induction of angiogenesis by 2 X l OS of non treated hUl11tlll runlor cells. 
(" Human IL-12 was added for 72 h into the cultures of human tumor cells at the concelltration of ' 1 ILg/1111 followed by cell injection (1 X 105 per single illjcction) into nontrca[ed 
Dalb/c mice. 
Proliferation Assay Tumor cell proliferation was studicd by mcans of 
f' HJthymidinc uptake. as described previously (Mqjewslci el ai, 1994). Cell s 
wcre seeded onto 96-well microtitcr plates (Nunc, Denmark) at a density of 
104 cells per well in 0.2 ml of complete cul tured medium supplemented 
with human Or murine lL-12 (0.1-1.0 f.Lg/m l). All cul tures we re set in six 
repHcates. Aftcr 48 h cu lcures were pulsed with 1 f.LCilml of[:lH]thymidine 
(Amersham, Aylesburg, UK) for 24 h fo llowed by scintillation counting 
(1409 Scintillation Counter; LKB-Wallac, Gaithersburg, MD) . The cpms 
obtained from various experimental groups were compared statistically. and 
the results were expressed as a percentage of an appropriate control value. 
RESULTS AND DISCUSSION 
Dose- and Time-Dependence of Autiangiogenic Effect of 
IL-12 This study confirms the potent antiangiogenic capacity of 
l L-12 ill lIillO, as shown previously in a model of mouse corneal 
vascu larization induced by one of th e angiogenic factors-bFGF 
(Voest et ai , 1.995). We used a m odel of tumor cell-induced 
an giogen esis in h eavily immunosuppressed Ba lb /c mice that per-
mits to exclude immunomodulatory m ech an ism ofIL-12 activity in 
the inhibition of an giogenesis. 
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Figure 2 . Counteracting effect of the neutralizing anti-mouse 
IFNy antibody on the inhibitory effect of murine IL-12 on T47D 
cell-induced angiogenesis. T he anti-IFN antibody at the concentration 
of l00 f.Lg pcr mouse was injected i.p. in to J3alb/c mice for three consecutive 
days after angiogenesis induction. Two hours after the anti-IFN antibody 
administration, the animals were treated i.p. with m1L-12 (1 f.Lg per 
injcctio n). Angiogenesis is expressed as l11 can ::!: SO nUlnbcr of newly 
formed blood vessels per single site of i.d. injection of CUmor cells. In 
parentheses arc number of injcction sites. * , statistica l1 y signjficant decrease 
in angiogenesis as compared to the control, at I' < 0.001. T he experimental 
groups represented by the bars 2 and 3 differ significantly at p < 0.001. 
T he studies showed that IL-1 2 strongly, in a dose-dependenr 
manner, inhi bited angiogenesis induced by human tumor cells of 
various origin, including tumorigenic ceUs h arboring integrated 
HPV DNA (Fig 1). In contraSt, n Oll tum origenic HPV DNA-
harboring celJs, w hich induced a weaker angiogenesis, were found 
to be not sen sitive to th e inhibitory effect of IL-12 (Table I). Thi 
is in agreement with our previous studies showing that nontumori-
genic Skv cells are not sensitive to an tiangiogenic effect of various 
re tilloids, IFNll' and vitamin D3 ana logs (Mltiewski e( ai, 1994, 
1995). Also nontransfonned human fibrob lasts, w hich evoked che 
lowest vascular response, were nonsusceptible to the inhibitory 
effec t of IL-12 (Table I) . The reason for the varying sensi tivity of 
tumor cells to antian giogenic action of IL-12 is unknown . It is 
conceivable that this could b e related to differen ces in the produc-
t ion and/or release of angiogenic factors by cells of different 
tumorigenic potential. T h e most potent ;/1 IIillo angiokines (VEGF 
and bFGF) were detected in h.igh amoun ts in a variety of human 
tumors, including those arising from the breast and HPV-associated 
cervica l carcinoma (Dvorak et ai, 1991; G uidi ef ai, 1995). More-
over ;/1 situ expression ofVEGF correlates w ith tumor invasiveness, 
and a mltiority of cases of invasive carcinomas of the cervix and 
high-grade intraepithelial lesions stron gly expressed VEGF mRNA, 
whereas benign epithe lial and low-grade squamous intraepithelial 
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Figure 3. Effect of 72-h preil.lcubatioll of tumorigenic A431 and 
Skv cells ill vitro with human IFNy (1000 U/ml) on the i" vi.," 
angiogenic capacity of these cells, injected i.d. iuto un treated 
mice. Angiogenesis is expressed as mean ::':: SD number of newly fonned 
blood vessels per single site of i.d. injection of tUlllor cell s. In parentheses 
are number of injection sites. *, statistically signifi cant difference at p < 
0.001. 
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lesions expressed only focal and low level ofVEGF mRNA (Guidi 
el ai, 1995) . 
Murine IL-12 was administered at various times before and after 
induction of angiogenesis, and the best results were obtained when 
this cytokine was given at the day of tumor cell injection and for 
rwo consecutive days. Under these conditions, the angiogenic 
capacity of aU tested tumorigenic ce ll lines (T47D, A431, Skv-tu) 
was equally inhibited by mIL-12 (Table I) . It cou1d be presumed 
that the inhibitory action of ll.-12 is most pronounced by its 
adminis tration dudng the process of new blood vesse l formation, 
starting on the day of angiogenesis induction. Pretreatment of mice 
with IL-12 before induction of angiogenesis might be due to 
elirrllnation of putative lL-12-induced antiangiogenic f.1ctors. It is 
to be stressed that antiangiogenic effect ofIL-12 was not due to its 
possible toxicity, and during 5 days of systemic administration of 
this cytokine, no significant body weight loss could be observed in 
the group of all treated Balb/c mice (23.5 :t:: 0 .5 g before vs. 23.9 
+ 0.8 g after treatment). 
ll--12 Does Not Directly Affect Tumor Cells In order to 
examine direct effects ofIL-12 on human tumor cell lines, the cells 
were incubated ill v itro for 72 h with m1L-12 followed by i.l-Uec tion 
of the preincubated cells into non treated animals. This procedure 
did not result in sign.ificant inhibition of angiogenesis induced by 
T47D cell line (26.3 :t:: 1.7 for control and 25.3 :t:: 1.5 for 
mIL-12-treated groups) . Similar results were obtained for A431 cell 
line (26.4 :t:: 2.1 I}S. 26.6 :t:: 1.3, respectively). Neither mIL-12 nor 
hIL-12 significancly decreased proliferation of human tumor cells ill 
vitro, and at the highest concentration used (1 J.Lg/ml) prolife ration 
of T47D cells reached 95% and 92% of the control values, 
respectively. Similar results were obtained with the use of the other 
cell lines (data not shown). Also Brunda et al (1993) have shown 
that IL-12 does not inhibit tumor cell proliferation ill vitro. These 
results pataUel the study by Voest cl al (1995), who dem onstrated 
that IL-12 has no direct effect on endothelial cell prolife ration . 
Our studies have also shown that administration of hIL-12 to 
mice, or incubation. of tumor cells with IL-12 prior to their 
inoculation, did not affect tumor cell-induced angiogenesis (Table 
II). These results confirm the species speci.ficity of IL-12 . More-
over, the fact that no direct effect offL-12 on tumor cells could be 
demonstrated ill l1itm suggests that some factors generated ill villo 
could mediate 3ntiangiogenic effects of IL-12. 
IFN1' Partially Mediates Antiangiogenic Effect of IL- 12 
Similar to Voest et al (1995), we found that the antiangiogenic effect 
of IL-12 could be counteracted by anti-IFNy neutralizing antibody 
(Fig 2) . Recent studies have shown that systemic administration of 
mIL-12 into the mouse results in high serum levels ofIFNy (Gately 
eJ ai, 1994) and IL-12 induces tumor regression in association with 
lFNl' production (Nastala cf aI, 1994b). The exac t mechanism of 
IFNl' action on angiogenesis is unknown . It was suggested that this 
cytokine might inhibit endothelial ce ll proliferation directly (Sato ct 
aI, 1990) or indirectly (via induction of protein IP-IO) (Voest et al. 
1995). IFNy could also exert <1ntiangiogenic effects through inhi-
bition of·synthesis of metalloprote inases and some components of 
extracellu1ar matrix (Sato ef aI, 1990) . In addition IFN y may act by 
its direct effect on production and/or release of some angiogenic 
factors from tumor ce lls, as shown in the experiments ill Ilitfo (Fig 
3). The latter mechanism is unknown and requires further studies. 
Recently, it was shown that IFNy is required for optimal antitumor 
effects ofIL-12, however, the induction oflFNy by IL-12 is not by 
itself sufficient to explain a marked antitumor activity of IL-12 
(Brunda et aI, 1995). Thus. it is possible that other than IFNy 
cytokines and/or signaling events are critical for antitumor efficacy 
of IL-12. 
In conclusion, Our results show that rL-12 is a potent inhibitor of 
tumor cell- induced angiogenesis ill l1illO, and that this antiangio-
genic effec t is not related to the immunostimulatory ac tivity. IL-12 
may be useful in the treatment of angiogenesis-dependent malig-
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nancies, especially in combination with other antiangiogenic com-
pounds , such as retinoids IFN a, or vitamin D 3 analogs. 
T " e s/IId)1 "'as slIppo/1ed b)1 a Crmlf 4-P05B-019-09 from tile Polis" COllllll iltee 
}in'Scielllific R esearc" . 
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